Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Vitrakvi (larotrectinib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Bayer, Pfizer

Drug class:

TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor

Related drugs:

‹

entrectinib (178)

taletrectinib (5)

entrectinib (178)

taletrectinib (5)

›

NTRK3 fusion	Sarcoma	NTRK3 fusion	Sarcoma	larotrectinib Sensitive: A1 - Approval larotrectinib Sensitive : A1	larotrectinib Sensitive: A1 - Approval larotrectinib Sensitive : A1
NTRK2 fusion	Sarcoma	NTRK2 fusion	Sarcoma	larotrectinib Sensitive: A1 - Approval larotrectinib Sensitive : A1	larotrectinib Sensitive: A1 - Approval larotrectinib Sensitive : A1
NTRK1 fusion	Sarcoma	NTRK1 fusion	Sarcoma	larotrectinib Sensitive: A1 - Approval larotrectinib Sensitive : A1	larotrectinib Sensitive: A1 - Approval larotrectinib Sensitive : A1
NTRK3 fusion	Solid Tumor	NTRK3 fusion	Solid Tumor	larotrectinib Sensitive: A1 - Approval larotrectinib Sensitive : A1	larotrectinib Sensitive: A1 - Approval larotrectinib Sensitive : A1
NTRK2 fusion	Solid Tumor	NTRK2 fusion	Solid Tumor	larotrectinib Sensitive: A1 - Approval larotrectinib Sensitive : A1	larotrectinib Sensitive: A1 - Approval larotrectinib Sensitive : A1
NTRK1 fusion	Solid Tumor	NTRK1 fusion	Solid Tumor	larotrectinib Sensitive: A1 - Approval larotrectinib Sensitive : A1	larotrectinib Sensitive: A1 - Approval larotrectinib Sensitive : A1
No biomarker	Solid Tumor	No biomarker	Solid Tumor	larotrectinib Sensitive: A1 - Approval larotrectinib Sensitive : A1	larotrectinib Sensitive: A1 - Approval larotrectinib Sensitive : A1
NTRK1 fusion	Thyroid Gland Follicular Carcinoma	NTRK1 fusion	Thyroid Gland Follicular Carcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK2 fusion	Thyroid Gland Follicular Carcinoma	NTRK2 fusion	Thyroid Gland Follicular Carcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK3 fusion	Thyroid Gland Follicular Carcinoma	NTRK3 fusion	Thyroid Gland Follicular Carcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK3 fusion	Pancreatic Adenocarcinoma	NTRK3 fusion	Pancreatic Adenocarcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK2 fusion	Pancreatic Adenocarcinoma	NTRK2 fusion	Pancreatic Adenocarcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2